Lumos Pharma, Inc. Common Stock
LUMO
LUMO was delisted on the 11th of December, 2024.
152 hedge funds and large institutions have $590M invested in Lumos Pharma, Inc. Common Stock in 2015 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 59 increasing their positions, 41 reducing their positions, and 18 closing their positions.
125% more call options, than puts
Call options by funds: $48.1M | Put options by funds: $21.4M
44% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 41
4% more capital invested
Capital invested by funds: $569M → $590M (+$20.7M)
0% more funds holding
Funds holding: 152 → 152 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$9.22M |
| 2 |
O
OrbiMed
New York
|
+$8.79M |
| 3 |
Millennium Management
New York
|
+$8.46M |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$4.98M |
| 5 |
TA
Teachers Advisors
New York
|
+$4.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$14.8M |
| 2 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$9.49M |
| 3 |
TAM
Tiverton Asset Management
Wilimington,
Delaware
|
-$6.85M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$4.17M |
| 5 |
Renaissance Technologies
New York
|
-$3.66M |
LUMO Hedge Fund Activity: Q4 2015 in Review
152 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q4 2015, worth a combined $590M — up 3.6% from $569M a quarter earlier.
Fund positioning in LUMO was balanced in Q4 2015: 18 funds opened new positions, 18 closed out, 59 added to existing stakes and 41 trimmed.
The largest buyer was Acadian Asset Management, adding an estimated $9.22M. The largest seller was Fidelity Investments, cutting an estimated $14.8M.
- 152 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q4 2015, unchanged from Q3 2015.
- Funds reported $590M of Lumos Pharma, Inc. Common Stock stock for Q4 2015, up 3.6% quarter-over-quarter.
- 18 funds opened new Lumos Pharma, Inc. Common Stock positions in Q4 2015 and 18 closed out, a net change of 0 holders.
- The largest Lumos Pharma, Inc. Common Stock buyer in Q4 2015 was Acadian Asset Management, an estimated $9.22M added.
- The largest Lumos Pharma, Inc. Common Stock seller in Q4 2015 was Fidelity Investments, an estimated $14.8M sold.
Based on aggregated 13F filings for Q4 2015.